Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy

  • K. Logmin
  • A. S. Moldovan
  • S. Elben
  • A. Schnitzler
  • S. J. GroissEmail author
Letter to the Editors

Dear Sirs,

A 56-year-old man presented with a 6 month history of dysarthrophonia, orofacial dyskinesia and chorea of both hands. His wife reported snoring, day sleepiness, insomnia and limb movements during sleep. The patient and his wife negated a cognitive impairment at the time of presentation. Mood was unimpaired.

Neurological examination showed oculomotor dysfunction (saccadic pursuit, absent vertical optokinetic nystagmus and delayed horizontal optokinetic nystagmus in routine examination), dysarthrophonia, orofacial dyskinesia and chorea.

The patient scored 28 of 30 points on the Montreal Cognitive Assessment Score (MoCA). Additional neuropsychological assessment showed abnormalities in alertness, information processing speed, selective attention and verbal memory. Unified Huntington’s Disease Rating Scale motor score (UHDRS-MS), used as a measure for hyperkinesia, was 17 of 124 points.

Cerebral MRI showed a macroadenoma of the pituitary gland but was otherwise unremarkable....



The authors thank J Enczmann for testing the HLA types of the patient and for giving the permission for publishing these results.

Compliance with ethical standards

Conflicts of interest

The authors have no conflicts of interests to report.

Ethical standards

The study was performed in accordance with the Declaration of Helsinki.

Informed consent

The patient gave his consent to publish the case report.


  1. 1.
    Simabukuro MM, Sabater L, Adoni T et al (2015) Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm 2:e136CrossRefGoogle Scholar
  2. 2.
    Gaig C, Graus F, Compta Y et al (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88:1736–1743CrossRefGoogle Scholar
  3. 3.
    Sabater L, Gaig C, Gelpi E et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13:575–586CrossRefGoogle Scholar
  4. 4.
    Honorat JA, Komorowski L, Jacobs KA et al (2017) IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4:e385CrossRefGoogle Scholar
  5. 5.
    Haitao R, Yingmai Y, Yan H et al (2016) Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol 300:9–10CrossRefGoogle Scholar
  6. 6.
    Bonello M, Jacob A, Ellul MA et al (2017) IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm 4:e383CrossRefGoogle Scholar
  7. 7.
    Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with Anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165CrossRefGoogle Scholar
  8. 8.
    Irani SR, Stagg CJ, Schott JM et al (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136(Pt 10):3151–3162CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurology, Medical FacultyHeinrich-Heine University DüsseldorfDüsseldorfGermany
  2. 2.Institute of Clinical Neuroscience and Medical Psychology, Medical FacultyHeinrich-Heine University DüsseldorfDüsseldorfGermany

Personalised recommendations